GS
Publicaties op Oncologisch.com
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wil...
Molecular hyperselection for optimal choice of eerstelijns targeted therapy independent of primary tumor sidedness: A...
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab bij gemetastaseerd colorectaal carcinoom: FIRE-3 post-hoc analyse